Skip to main content
Novartis Home

Language & Country Selector for Desktop

language-selector-globe Global | en

Choose Location

  • International
  • Americas
  • Asia Pacific
  • Europe
  • Middle East & Africa
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Argentina | es
  • Brazil | pt
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Mexico | es
  • United States | en
  • Venezuela | es
  • Australia | en
  • Bangladesh | en
  • Hong Kong S.A.R. | zh
  • India | en
  • Indonesia | en
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Malaysia | en
  • Pakistan | en
  • Philippines | en
  • Singapore | en
  • Taiwan | zh
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Bulgaria | bg
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hungary | hu
  • Ireland | en
  • Italy | it
  • Latvia | lv
  • Lithuania | lt
  • Netherlands | nl
  • Norway | no
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • United Kingdom | en
  • Egypt | en
  • Israel | he
  • South Africa | en
  • Turkey | tr

Language & Country Selector for Mobile

language-selector-globe Global

Choose Location

International Americas Asia Pacific Europe Middle East & Africa
  • Argentina | es
  • Australia | en
  • Austria | de
  • Bangladesh | en
  • Belgium | fr
  • Belgium | nl
  • Brazil | pt
  • Bulgaria | bg
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Egypt | en
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hong Kong S.A.R. | zh
  • Hungary | hu
  • India | en
  • Indonesia | en
  • Ireland | en
  • Israel | he
  • Italy | it
  • Japan | ja
  • Korea | ko
  • Latvia | lv
  • Lithuania | lt
  • Mainland China | zh
  • Malaysia | en
  • Mexico | es
  • Netherlands | nl
  • Norway | no
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Pakistan | en
  • Philippines | en
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Singapore | en
  • Slovakia | sk
  • South Africa | en
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • Taiwan | zh
  • Turkey | tr
  • United Kingdom | en
  • United States | en
  • Venezuela | es
    • About 
      • Board of Directors 
        • Joerg Reinhardt 
        • Simon Moroney 
        • Nancy Andrews 
        • Ton Buechner 
        • Patrice Bula 
        • Elizabeth Doherty 
        • Ana de Pro Gonzalo 
        • Bridgette Heller 
        • Daniel Hochstrasser 
        • Frans van Houten 
        • Andreas von Planta 
        • Charles Sawyers 
        • William Winters 
        • Charlotte Pamer-Wieser 
      • Executive Committee 
        • Vasant (Vas) Narasimhan 
        • Shreeram Aradhye 
        • Victor Bulto 
        • Aharon (Ronny) Gal 
        • Karen L. Hale 
        • Harry Kirsch 
        • Rob Kowalski 
        • Steffen Lang 
        • Fiona Marshall 
        • Klaus Moosmayer 
        • Marie-France Tschudin 
        • Lutz Hegemann 
        • Kees Roks 
        • Richard Saynor 
        • Michael Willi 
      • Strategy 
        • People and Culture 
        • Data and Digital 
      • Products 
      • Innovative Medicines 
      • Sandoz 
      • Diversity, Equity & Inclusion 
        • Equity 
        • Diversity, Equity & Inclusion Governance and Community 
        • Inclusivity 
        • Parental Leave 
        • Society 
      • Manufacturing 
      • Quality 
        • Audit program 
        • Novartis Quality Management System (QMS) 
        • Product and patient safety training 
        • Regulatory inspections 
        • Product recalls 
        • Third-party suppliers 
      • Awards and Recognition 
      Male scientist in lab About Novartis
    • Patients and Caregivers 
      • Novartis Commitment to Patients and Caregivers 
      • Diseases 
      • Patient Organization Funding 
      • COVID-19: Patients and Caregivers 
      • Stories: Patients Perspectives 
      Couple holding hands Patients & Caregivers
    • Healthcare Professionals 
      • Medical Congresses and Events 
        • Abstract summaries for EULAR 
        • Abstract summaries for ACR 
        • Abstract summaries for EADV 
      • Products 
      • Novartis Pipeline 
      • Managed Access Programs 
        • Novartis Gene Therapies Managed Access Program 
      • Novartis External Funding 
      • Healthcare Professional Resources by Country 
      • Investigator-Initiated Trials / Studies 
      • Transparency and Disclosure 
      • Novartis Medical Information 
        • Submit medical enquiry 
      Doctor Healthcare Professionals
    • Research & Development 
      • Novartis Institutes for BioMedical Research 
        • Collaborations 
        • NIBR Global Scholars Program 
      • Technology Platforms 
        • Radioligand Therapy 
        • Gene Therapy 
        • Cell Therapy 
      • Research Disease Areas 
        • Immuno-oncology research at Novartis 
        • Oncology research at Novartis 
        • Cardiovascular and metabolic disease research at Novartis 
        • Autoimmunity, transplantation and inflammatory disease research at Novartis 
        • Ophthalmology research at Novartis 
        • Neuroscience Research at Novartis 
        • Musculoskeletal Disease Research at Novartis 
        • DAx: exploratory disease research at Novartis 
      • Research Locations 
        • Novartis Institute for Tropical Diseases 
      • Novartis Pipeline 
      • Translational Medicine 
      • Research & Development Approach 
      • Research Collaborations 
      • Open Source Science 
      • Stories from our Labs 
      Scientists conducting innovative research experiments Research & Development
    • ESG 
      • Access 
        • Creating sustainable business models 
        • Value-Based Pricing 
        • Sub-Saharan Africa 
        • Donations 
        • Novartis Access Principles 
        • Novartis Oncology Access 
        • Patents and Licensing 
      • Ethics, Risk and Compliance 
        • Ethical Behavior 
        • Compliance 
        • Human Rights 
        • Learning and Engagement 
        • Risk management 
      • Environmental Sustainability 
        • Climate 
        • Waste 
        • Water 
      • Global Health 
        • Anti-Microbial Resistance (AMR) 
        • Avoidable Blindness 
        • Chagas Disease 
        • Leprosy 
        • Malaria 
        • Sickle Cell Disease (SCD) 
        • Novartis Foundation 
      • Diversity, Equity & Inclusion 
      • Reporting 
        • ESG Rating Performance 
        • Codes, Policies and Guidelines 
        • Materiality Assessment 
        • Transparency and Disclosure 
        • Targets 
        • Positions 
      • ESG Index 
      Young patients waiting outside an hospital in Rwanda Environmental, Social and Governance
    • Investors 
      • Event Calendar 
      • Financial Data 
        • Novartis Annual Results 
        • Novartis Quarterly Results 
        • Novartis SEC Filings 
        • Product Sales 
        • Fixed-Income Securities 
        • Expected Currency Impact 
      • Share Data & Analysis 
        • Share Monitor 
        • Dividend Information 
        • Share Ownership 
        • Share Overview 
        • Return On Investment Calculator 
      • Shareholder Information 
        • General Meetings 
        • American Depository Receipts (ADR) 
        • Share Buy-Back 
        • Frequently Asked Questions 
      • Company Overview 
        • Corporate Governance 
      • Novartis Annual Reporting Suite 
        • Reporting Archive 
        • Publications Order Form 
      • ESG 
      Hands marking a test tube Investors
    • News 
      • News Archive  
      • Media Library  
      • Stories 
      • Subscribe 
      People at the table with screens News
    • Careers 
      • Career Search 
      • Our Teams 
        • Careers in Commercial 
        • Careers in Communications and Engagement 
        • Careers in Consulting 
        • Careers in Digital 
        • Careers in Health, Safety & Environment 
        • Careers in Information Technology (IT) 
        • Careers in Medical & Development 
        • Careers in People & Organization 
        • Careers in Procurement 
        • Careers in Research 
        • Careers in Strategy 
        • Careers in Manufacturing and Supply 
        • Ethics, Risk & Compliance (ERC) 
        • Careers in Legal 
      • Career Programs 
        • Community Exploration & Learning Lab (CELL) 
        • Postdoc Program 
      • Early Talent 
        • US NIBR Internship Programs 
      • International Careers 
      • Personal Growth 
      • Well-being 
      A female Novartis researcher Careers
    • Clinical Trials 
      doctor taking the blood pressure of her patient Clinical Trials
    • Partnering 
      Business people working in a dark room Partnering
    • Supplier Portal 
    • Report side effects 
    • Contacts 
      Office Cubicle Contacts
    Group of scientists working in a lab in winter Home

Stories

Story Navigation
  • All Topics
  • Discovery
  • From Our Labs
  • Patient Perspectives
  • Access to Healthcare
  • People & Culture
icon
  • Molecular glue kills cancer cells in mice
    From Our Labs
    Biomedical ResearchDrug DiscoveryNovartis Institutes for BioMedical ResearchReimagine MedicineNew Scientific Discoveries
    Jul 19, 2021
    Molecular glue kills cancer cells in mice

    Compounds block a protein involved in many cancers by cementing it shut.

    From Our Labs
  • Tuning drugs to succeed on the cell’s surface
    From Our Labs
    Biomedical ResearchDigitalDrug DiscoveryNovartis Institutes for BioMedical ResearchPostdoc ProgramDrug Design
    Jul 20, 2021
    Tuning drugs to succeed on the cell’s surface

    Researchers improve our understanding about how compounds bind to proteins in the cell membrane—and the membrane itself.

    From Our Labs
  • Building brain organoids to shed light on disease
    From Our Labs
    Biomedical ResearchNovartis Institutes for BioMedical ResearchPostdoc ProgramScientific Discoveries
    Jul 19, 2021
    Building brain organoids to shed light on disease

    Three-dimensional clusters of human neurons could allow scientists to watch neurological diseases develop in the lab.

    From Our Labs
  • Special Olympian Ryan Groves suffers from TSC, a genetic condition that afflicts nearly 1 million patients worldwide.
    From Our Labs
    Biomedical ResearchMedical InnovationsNovartis Institutes for BioMedical ResearchPostdoc Program
    Jul 19, 2021
    With a "brain in a dish," researchers take on neurological disorders

    Neurological diseases develop out of sight. Novartis neuroscientists are bringing them into the light, using human brain cells grown in the lab.

    From Our Labs
  • Electrical brainstorms traced to genetic mutations
    From Our Labs
    Biomedical ResearchGene SequencingNovartis Institutes for BioMedical ResearchReimagine MedicineNext Generation SequencingGenetic Disease
    Jul 19, 2021
    Electrical brainstorms traced to genetic mutations

    Researchers from Seattle Children’s and Novartis shed light on developmental brain disorders that lead to intractable epilepsy.

    From Our Labs
  • Eye disease tracked to a glitch in starburst cells
    From Our Labs
    Novartis Institutes for BioMedical ResearchNew Scientific DiscoveriesScientific ResearchGenetic Disease
    Jul 19, 2021
    Eye disease tracked to a glitch in starburst cells

    A cellular computing error wreaks havoc on vision.

    From Our Labs
  • Hooked on science, Jay Bradner becomes top researcher at Novartis
    From Our Labs
    Biomedical ResearchDrug DiscoveryNovartis Institutes for BioMedical ResearchReimagine MedicineNew Scientific DiscoveriesScientific Research
    Jul 19, 2021
    Hooked on science, Jay Bradner becomes top researcher at Novartis

    New NIBR President Jay Bradner shares on drug discovery, his leadership style and what’s next for his career in biomedical research.

    From Our Labs
  • When tiny brains are best for brain research
    From Our Labs
    Biomedical ResearchDrug DiscoveryNeuroscienceNovartis Institutes for BioMedical ResearchPostdoc ProgramGenetic Disease
    Jul 20, 2021
    When tiny brains are best for brain research

    Zebrafish imaging sheds light on human neurological conditions.

    From Our Labs
  • Five reasons to kill a projekt
    From Our Labs
    Drug DiscoveryNovartis Institutes for BioMedical ResearchPostdoc ProgramScientific ResearchCareersClinical Trials
    Jul 19, 2021
    5 tips for making smart decisions on research projects

    Make smart decisions about your research projects.

    From Our Labs
  • CRISPR genome editing fuels cancer drug discovery
    From Our Labs
    Novartis Institutes for BioMedical ResearchReimagine MedicineCancer Research Institute
    Jul 19, 2021
    CRISPR genome editing fuels cancer drug discovery

    Genome editing advances drug discovery in biomedical research.

    From Our Labs
  • Rediscovering the power of nature’s exquisite complexity
    From Our Labs
    Drug DiscoveryGene SequencingNovartis Institutes for BioMedical ResearchClinical ResearchBiomedical JobsDrug Design
    Jul 20, 2021
    Rediscovering the power of nature’s exquisite complexity

    Read how nature's medicine chest empowers our drug discovery chemists to advance biomedical research

    From Our Labs
  • Opening chemistry education to the world
    From Our Labs
    Drug DiscoveryNovartis Institutes for BioMedical ResearchTropical DiseasesClinical ResearchBiomedical JobsEye Disorders
    Jul 20, 2021
    Opening chemistry education to the world

    Novartis taps MOOC technology to share chemistry education with the world

    From Our Labs

Pagination

  • ‹ Previous page
  • 1
  • 2
  • 3
  • 4
  • 5
  • › Next page

Novartis

Navigate Novartis
  • Patients and Caregivers
  • Healthcare Professionals
  • Researchers
  • Job Seekers
  • Journalists
  • Investors
  • Partners
  • Suppliers
Topics
  • Clinical Trials
  • COVID-19 Info Center
  • ESG
Explore
  • Stories
  • Diseases
  • Locations
  • Products
  • Novartis Pipeline
Novartis companies
  • Sandoz
  • Advanced Accelerator Applications
  • Gyroscope Therapeutics
Footer Bottom
© 2023 Novartis AG
  • Terms of Use
  • Privacy
  • Contacts
  • Cookie Settings
  • Site Map
  • Web Accessibility
  • Open Source
Novartis Site Directory
This site is intended for a global audience